Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Penn Capital Management Company LLC

Penn Capital Management Company LLC trimmed its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 63.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,658 shares of the company’s stock after selling 67,433 shares during the period. Penn Capital Management Company LLC’s holdings in Elanco Animal Health were worth $480,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its position in Elanco Animal Health by 28.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock valued at $124,000 after purchasing an additional 2,264 shares during the period. DDD Partners LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at about $5,974,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after buying an additional 209,734 shares during the period. Franklin Resources Inc. boosted its stake in shares of Elanco Animal Health by 14.0% in the third quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock worth $5,349,000 after buying an additional 45,795 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after acquiring an additional 2,059 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Barclays decreased their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Stifel Nicolaus dropped their price target on shares of Elanco Animal Health from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. UBS Group decreased their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $14.67.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was acquired at an average price of $10.90 per share, with a total value of $109,000.00. Following the completion of the acquisition, the director now directly owns 101,459 shares of the company’s stock, valued at $1,105,903.10. This represents a 10.93 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $9.45 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a market capitalization of $4.69 billion, a PE ratio of 23.63, a P/E/G ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.80. The company has a fifty day moving average of $10.07 and a two-hundred day moving average of $11.69.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the company earned $0.08 EPS. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.